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much in correct reporting of statistical parameters, except 
sample size and number of primary endpoints. 
This study has some limitations, one of which is its small 
sample size (Indian medical journals and clinical trials) for 
analysis. Another limitation here was difficulty in knowing 
the time of intervention by statisticians, whether he/she 
has contributed from the start of the clinical trial (design 
phase) or only during analysis of results. Another limitation 
may be under-reporting of the role of statistician. In this 
study, Bonferroni correction was used for adjustment of 
multiple endpoints. This method of adjustment becomes 
less reliable, as the number of endpoints increase.  
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Pharmacovigilance: A 
Worldwide Master Key for 
Drug Safety Monitoring: Some 
Additional Information
Sir,
I have read the article titled “Pharmacovigilance: A 
worldwide master key for drug safety monitoring,” and 
I found the topic quite informative and it also included 
recent updates. So first of all, I congratulate the authors 
for such a nice compilation. It covers almost all areas; 
however, I would like to add more information about 
pharmacovigilance in vaccines. The great challenge here 
is to convey a proper message to the general public as 
it is like a double-edged sword.[1] Majority of vaccines 
are administered to vulnerable (children) as well as 
healthy population that requires strict safety supervision. 
Therefore, the safety of a vaccination must be more than 
other pharmacological agents to make it acceptable in 
general population.[2]
According to WHO, the adverse event following 
immunization (AEFI) is “a medical incident that takes place 
after an immunization causes concern, and is believed to be 
caused by the immunization.” Vaccines are biological agents 
given prophylactically to protect target population again 
specific infection by immunological action.[2] Following 
points favor different pharmacovigilance for vaccines and 
drugs:
1.  Complex vaccine sources
  Vaccines are complex biological products, which may 
include multiple antigens, live organisms, adjuvants, 
and preservatives. Adverse drug reactions (ADRs) may 
be due to the administration of live wild viruses, e.g., 
lymphocyte meningitis after anti-mumps vaccine or 
may be non-specific, related to a component different 
from the antigen (aluminum hydroxide involved in 
Table 1: Difference between various statistical parameters between both groups
Frequencies→
Groups ↓ 
Sample size 
calculated
Sample size 
(Mean (SD))
Calculation of 
Power
Appropriate 
statistical tests
Significant P value 
after Bonferroni 
correction
Post hoc >80% 
power for large 
difference
Number of 
Primary endpoints   
(Mean (SD))
Statistician (n=13) 7 (53.8) 58.8 (24.2) 7 (53.8) 12 (92.3) 9 (69.2) 11 (84.6) 1.42 (0.51)
Non Statistician (n=55) 22 (40) 41.8 (23.3) 20 (36.3) 50 (90.9) 30 (54.5) 41 (74.5) 2.16 (0.89)
P value 0.36 0.019 0.24 0.87 0.33 0.48 0.005
Statistical test Chi-square test Unpaired t test Chi-square test Chi-square test 
(Yates correction)
Chi-square test 
(Yates correction)
Chi-square test 
(Yates correction)
Unpaired t test
Values in parentheses are percentages
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the “macrophagic myofasciitis,” allergic reactions to 
neomycin, latex, egg, or gelatin).[3]
2.  Different modes of causality assessment 
  There are some issues, which make evaluation of 
vaccines different from other drugs. Local or immediate 
adverse reactions, which occur due to administrative 
error and attenuated virus, can be attributed with a 
degree of confidence but delayed events are difficult 
to correlate. They have immunological considerations 
in addition to pharmacological action and take a long 
time to respond.[3] Criteria commonly used to determine 
causality such as resolution of the event following 
treatment discontinuation and the result of rechallenge 
cannot be used to assess causality of an event occurring 
after vaccination.[4]
3.  Difference between reporters and reporting chain
  This suggests big communication gap, which requires 
immediate modification in the current system. 
  So, it is high time to change the current strategy for 
pharmacovigilance of vaccines as considerable research 
is going on for vaccine development in infectious 
diseases, e.g., HIV, malaria, H1N1, etc. having high 
patient load.[2]
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A free application to browse and search the journal’s content is now available for Android based 
mobiles and devices. The application provides “Table of Contents” of the latest issues, which 
are stored on the device for future offline browsing. Internet connection is required to access the 
back issues and search facility. The application is compatible with all the versions of Android. The 
application can be downloaded from https://market.android.com/details?id=comm.app.medknow. 
For suggestions and comments do write back to us.